Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Solid Tumor 1Recurrence 1Prostatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1

Interventions

Rituximab 47Cyclophosphamide 45fludarabine 22Filgrastim 21Lenalidomide 18fludarabine phosphate 17Prednisone 16Radiotherapy 15Peripheral Blood Stem Cell Transplantation 15Etoposide 15Vincristine 14Doxorubicin 14Melphalan 13Busulfan 13pembrolizumab 11Tacrolimus 11Methotrexate 10Gemcitabine 10ibrutinib 9Bendamustine Hydrochloride 9Alemtuzumab 9obinutuzumab 8Bortezomib 8Vorinostat 7Mycophenolic Acid 7Granulocyte Colony-Stimulating Factor 7Carboplatin 7Azacitidine 7venetoclax 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma × WW Domain-Containing Oxidoreductase × Clear all
NCT00481871 2020-01-07

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Acrotech Biopharma Inc.

Phase 1/2 Completed
119 enrolled 13 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡